Free Trial

Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11

→ Do you think trading w/emotion helps? (From Brooks Enterprises) (Ad)
Lucira stock price

Key Points

  • Lucira Health received FDA approval for a combination COVID-19 and flu test on Feb. 24, 2022.
  • COVID-19 tailwinds have dissipated with the reopening causing demand to fall precipitously for testing kits.
  • Shares are trading at a $5 million market cap, while annual revenues are expected to exceed $100 million.
  • The company had $39.8 million in cash at the end of Q3 2022 after a GAAP net loss of ($126.9 million).
  • The company filed voluntary Chapter 11 bankruptcy protection to expedite the sale of the business on Feb. 22, 2023.
  • 5 stocks we like better than Lucira Health

Lucira Health Inc. NASDAQ: LHDX shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its combination at-home COVID-19 and a flu test. The over-the-counter (OTC) 30-minute at-home rapid test can detect influenza A and B and the SARS-CoV-2 virus using nasal swabs.

This appears to be good news, but digging just a little deeper reveals that it's a case of too little and too late. The company had expected the FDA approval in August 2022, but the protracted approval process left the company bleeding through cash with high expenditures.

Lucira Health went public through an IPO on Feb. 5. 2021, at $22.10 per share and currently has 40 million shares outstanding While it blames the FDA for its slow approval of its combo test, the company has still been selling its COVID-19 test, which competes with rapid tests from Abbott Laboratories Inc. NYSE: ABT, Beckton, Dickinson & Co. Dickinson NYSE: BDX and QuidelOrtho Corp. NASDAQ: QDEL. The delay caused them to miss the U.S. 2022 to 2023 flu season, despite Canada approving the combo test. The bottom line is that the demand has been falling as COVID-19 falls further into the rearview mirror.

Big Charge-Offs

On November 14, 2022, Lucira Health released its Q3 2022 earnings for the quarter ending in September 2022. The company reported net revenues of $34.4 million, up 130% year-over-year (YoY). GAAP gross loss was ($99.6 million), compared to ($1.5 million) in the year-ago period. GAAP negative gross margin was (289%) versus (10%) for the year-ago period.

The excessive GAAP losses were from charges for overstocked inventory, non-cancellable purchase commitments, and prepaid inventory. GAAP net loss was ($126.9 million) compared to a loss of ($27.5 million) in Q3 2021.


The company took a non-cash inventory charge of (-$107.2 million) due to a significant sale forecast reduction stemming from the unanticipated delay of its combination test from the FDA. Lucira ended the quarter with $39.8 million in cash, down from $106 million at the end of 2021. 

During the quarter, Lucira executed a marketing agreement with Pfizer NYSE: PFE to increase awareness of the risks of COVID-19 and treatment options. The company received approval and launched its combination COVID-19 and flu test in Canada while still awaiting U.S. FDA approval, filed under Emergency Use Authorization (EUA) in May 2022.

Voluntary Chapter 11 Bankruptcy

On Feb. 22, 2023, Lucira Health announced the voluntary filing for protection under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The company will continue to operate daily and use cash on hand to fund operations. It intends to sell the business under Section 363 of the Bankruptcy code. It will continue to support customers throughout the process. In October 2022, the Board of Directors approved actions to rebalance its cost structure and consider selling the company.

While the company was able to trim costs, reduce headcount, and renegotiate some vendor contracts, the delay in the approval and subsequent revenues from the 2022 to 2023 flu season left the company in shambles.

Lucira CEO Erik Engleson commented, "Unfortunately, as restrictions lessened in 2022, we saw lower demand for COVID-19 tests. This, combined with slower-than-anticipated regulatory approval for the new combined test kit developed for the 2022-2023 flu season, led to insufficient revenue and capitalization to offset expenditures. Despite every effort to reduce capital outlays and restructure our business, we took this action to protect and maximize the value of our assets."

What Happens Next?

Chapter 11 is a way to protect the company from creditors as it operates on a day-to-day basis while planning a reorganization. Many companies have emerged from Chapter 11. Unfortunately, the common stock shareholders are often left holding worthless stock as new shares are issued. This was the case for General Motors Co. NYSE: GM Chapter 11 filing in 2009. This was also the case with American Airlines Chapter 11 filing in 2011.

After restructuring the company emerged from bankruptcy in 2013. When American Airlines issued new stock, the previous shareholders were stuck with worthless stock. The recent case of rental car giant The Hertz Corporation NASDAQ: HTZ emerged from Chapter 11 and resumed NASDAQ trading on November 9, 2021. Old shareholders got a package deal of cash, 3% stock of the new company, and warrants for 18% of the newly reorganized company.

Lucira needs to raise cash. It's trying to preserve as much cash as possible to buy enough time to launch sales of its combo test and find a buyer for the business. The expedited sale of the business awaits approval from the U.S. Bankruptcy Court. Unlike the earlier examples, Lucira plans to sell the business rather than go it alone and emerge from Chapter 11. This may be driving speculators to pile into the stock.

Gap and Crap or Gap and Go

The daily candlestick chart on LHDX illustrates the rollercoaster price action for Feb. 20, 2023. On Feb. 22, Lucira announced its voluntary Chapter 11 filing, causing shares to gap down and selloff to a low of $0.11 on Feb. 23. On Feb. 24, Lucira announced the long-awaited FDA approval for its combination COVID-19 and flu home test caused shares to surge over 700% off previous day lows to a high of $0.75 before closing at $0.52, up only 264% on a massive 278 million shares of the trading volume.

This was 6X of its total outstanding shares traded in a single day. The $0.87 is the weekly market structure low (MSL) trigger. Pullback support levels are $0.28, $0.17, and $0.11. Be aware that shares may be delisted during Chapter 11 but shares may spike on sentiment.   

→ Do you think trading w/emotion helps? (From Brooks Enterprises) (Ad)

Should you invest $1,000 in Lucira Health right now?

Before you consider Lucira Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lucira Health wasn't on the list.

While Lucira Health currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report
Jea Yu
About The Author

Jea Yu

Contributing Author

Trading Strategies

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Abbott Laboratories (ABT)
4.9785 of 5 stars
$105.72-0.8%2.08%32.93Moderate Buy$120.64
General Motors (GMM)
0 of 5 stars
C$0.00-100.0%N/AN/A
General Motors (GM)
4.799 of 5 stars
$47.72-0.1%1.01%5.83Moderate Buy$54.81
General Motors (GMM.U)
0 of 5 stars
C$0.00flatN/AN/AN/A
Pfizer (PFE)
4.7955 of 5 stars
$27.74flat6.06%-462.26Hold$35.86
QuidelOrtho (QDEL)
4.7035 of 5 stars
$35.21+1.1%N/A-1.33Hold$59.00
GAP (GPS)
4.1166 of 5 stars
$24.70-2.0%2.43%13.72Hold$25.86
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Recent Videos

The Power of Stock Buybacks: Investor Insights
NVIDIA Tops Microsoft and Apple for Most Valuable Company
Dividend Kings: The Secret to Steady and Growing Income

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines